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enhances the sensitivity of tumour cells to radiation, 
and it has also been established that the concurrent ad-
ministration of Cet and radiotherapy (Cet/RT) might 
result in some degree of interplay between the effects of 
the individual agents on the skin, resulting in the pos-
sible exacerbation of the usual reaction experienced 
with the individual agents given as exclusive therapeutic 
choice  [1, 2] . The pivotal phase III trial by Bonner et al. 
 [3, 4] demonstrated that the addition of Cet to RT re-
sults in a significant increase in locoregional control 
and survival compared to RT alone, even on a long-term 
basis.
 Moreover, the same trial did not show any statistical-
ly significant difference in terms of radiation dermatitis 
(either all grades or grade  ≥ 3) between the two treat-
ment arms, although a 5% trend towards an increase in 
the incidence of grade  ≥ 3 radiation dermatitis was de-
tected in the Cet arm  [3] . Conversely, some authors re-
port severe radiation-induced dermatitis-like skin reac-
tions with the combination of Cet/RT  [5–7] . We herein 
present a concise review of ‘in-field’ Cet/RT-related skin 
toxicity with a focus on pathogenesis, clinical presenta-
tion and scoring systems and, finally, therapeutic man-
agement.
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 Abstract 
 It is well known that the cetuximab (Cet) epidermal growth 
factor receptor (EGFR) antibody enhances the sensitivity of 
tumour cells to radiation, and it is likely that the concurrent 
administration of Cet and radiotherapy (RT) results in some 
degree of interplay between the effects of the individual 
agents on the skin and in the exacerbation of reactions nor-
mally seen with these individual agents. In this paper, we 
present a concise review of Cet/RT-related skin toxicity, fo-
cusing on mechanisms and pathogenesis, clinical presenta-
tion and scoring systems and, finally, therapeutic manage-
ment.  © 2013 S. Karger AG, Basel 
 Introduction 
 It is common knowledge that the antibody against 
the epidermal growth factor receptor (EGFR), namely 
cetuximab (Cet; Merck-Serono, Darmstadt, Germany), 
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 Materials and Methods 
 During April 2013, a non-systematic literature review of Cet-
induced dermal toxicity associated with RT in head and neck can-
cer patients was performed. The electronic databases used were: 
PubMed, The Cochrane Library, Scopus and Embase. The follow-
ing keywords were combined: dermatitis, cetuximab; EGFR; ra-
diotherapy; radiation; head and neck cancer. The electronic search 
results were supplemented by manual examination of reference 
lists from selected articles. The investigation focused on mecha-
nisms and pathogenesis, clinical presentation, scoring systems, 
and therapeutic management. The literature search was limited to 
articles in English and to human patients. We analysed and dis-
cussed the literature, taking into account the previously reported 
reviews on this subject.
 Cet/RT Interaction on Skin Toxicity: Pathogenesis 
 In-field skin reactions observed after Cet/RT thera-
peutic association present pathophysiological and clinical 
differences compared to those observed after exclusive 
radiation, since they are characterized by early onset, rap-
id resolution and usually no evidence of scars  [5, 8] . Con-
sidering Cet/RT association, the combination of skin re-
sponses to individual agents leads to a peculiar clinical 
presentation.
 RT primarily injures the proliferating basal layer of the 
epidermis, causing cell depletion and consequent altera-
tion in the physiological cell turnover. Granular cells and 
anucleated corneocytes show less radiosensitivity where-
as dermal inflammatory response cells and the peripheral 
nervous system are activated by the release of alarmins 
and cytokines  [9, 10] , provoking dermatitis (i.e. oedema) 
and local hypersensitiveness (pruritus, erythema, pain). 
The final result is an inflamed derma covered by a thinned 
epidermis.
 Epidermal thinning is mostly due to the stratum gran-
ulosum, involved in the production of lipids and natural 
moisturizing factors  [11] . This stratum cooperates with 
the corneal stratum in the prevention of transepidermal 
water loss  [2, 11] . The damage is visible as clumps of ex-
foliated corneocytes, characteristic of dry desquamation 
associated with grade 1 radiation dermatitis reaction.
 For high radiation doses, an almost complete loss of 
the basal cell, associated with a disruption of the base-
ment membrane, might occur, leading to exposure of the 
inflamed  [9] dermis and eventually to moist desquama-
tion, described as grade 2–3 reactions. Finally, skin necro-
sis or ulceration of the full-thickness dermis (grade 4 re-
actions) might occur, even though anecdotally, during 
the acute phase.
 The EGFR signalling pathway plays an integral part in 
the development and maintenance of the normal skin, 
regulating survival, migration and proliferation of the 
various types of epidermis cells  [12–14] . In vitro data 
show that EGFR inhibitors (EGFRis) reduce the prolif-
erative activity and migration ability within the basal 
cells, concurrently inducing early cellular differentiation 
and apoptosis  [5, 12] . Thus, EGFR inhibition leads to a 
thinning of the functional strata  [12, 15] , favouring the 
development of xerosis  [13, 16] . Furthermore, the block-
ade of the EGFR induces a deranged chemokine expres-
sion in keratinocytes, leading to enhanced skin inflam-
mation which is responsible for folliculitis and dermatitis 
 [17, 18] . Finally, it has been shown that EGFRis can alter 
the injury-induced innate immune response  [19] , com-
promising the synthesis of antimicrobial peptides  [16] 
and favouring microbial colonization and superinfection 
 [20] .
 Clinical Manifestations 
 Concurrent administration of Cet/RT might result in 
an exacerbation of skin reactions typical of individual 
agents, and interactions might manifest as a thinning of 
the epidermis, leading to a more frequent occurrence of 
microinjuries, marked xerosis and more intense inflam-
matory response. Necrosis has been described as focal 
and superficial  [13, 15] .
 Thus, the reinforced Cet/EGFRi inflammatory effect 
favours the production of an inflammatory exudation 
which, in consequence of the altered transepidermal wa-
ter loss barrier, dries off rapidly to form crusting exu-
dates. These crusts might adhere to the skin, cause dam-
age and provoke bleeding and/or pain  [21] . The repara-
tive capacity of damaged skin might also be compromised, 
rendering the cutis itself prone to abrasion. Finally, crusts 
may harbour bacteria, thereby potentially increasing the 
risk of superinfection, possibly exacerbated by the EGFRi 
deregulation effect on inflammatory immune reactions.
 The type of reaction observed following concurrent 
Cet/RT depends on the degree of interaction between the 
two treatments; the clinical manifestations vary from a 
combination of dry/moist desquamation, mainly related 
to RT, and xerosis, inflammation and innate immune de-
fence deregulation, associated with EGFRis. Whenever 
Cet is associated with RT, crusting exudation (sometimes 
associated with ‘spontaneous’ or ‘minor trauma’ bleed-
ing;  fig. 1 ) becomes evident mostly within in-field cutane-
ous areas.
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 During Cet/RT, the onset of radiation dermatitis may 
be earlier than with RT alone  [15, 22] , and the overall en-
tity of toxicity may be more severe in terms of dermati-
tis   [23] ; however, patients generally recover within 
1–2 weeks after treatment, even in the presence of crusts 
 [13, 24, 25] .
 Specifically, Cet might induce systemic skin toxicity: 
skin rash, skin dryness, xerosis, pruritus, hair abnormal-
ity, and nail changes  [25, 26] . The most common skin 
toxicity is a papulopustolar rash, which affects 60–80% 
of patients. It is generally mild to moderate, though se-
vere (G3–4) in 5–20% of patients  [25, 27] . Incidence and 
entity are usually dose related  [27] , and generally, it is 
reversible, with complete resolution within 4 weeks after 
treatment discontinuation or, in some cases, even dur-
ing maintained treatment; it may relapse or worsen at 
treatment restart. Papulopustular eruption consists of 
erythematous follicular papules which may potentially 
evolve into pustules. Lesions may coalesce into plaques 
covered by yellow crusts  [21] . Frequent infection of 
these lesions has been described  [20] . Skin xerosis is 
present in up to 35% of patients receiving EGFRis; it de-
velops over time, particularly in areas previously or si-
multaneously affected with papulopustolar eruption 
 [24] .
 Xerosis is often more widespread than skin rash; it may 
evolve into chronic asteatotic eczema, with erythema and 
worsening of pruritus. Xerosis and eczematous changes 
in the fingertips, palms and soles are usually associated 
with painful fissures.
 Scoring Systems of Dermatological Adverse Events 
 The National Cancer Institute Common Terminology 
Criteria for Adverse Events version 4.3 (NCI-CTCAE 
version 4.3) is an established tool for grading radiation 
dermatitis  [28] .
 Whereas it has proved suitable for grading dermatitis 
in patients receiving either RT or Cet, it is less appropri-
ate for grading the type of dermatitis seen in patients re-
ceiving both Cet/RT. Indeed, the grading of radioderma-
titis is often not applicable to in-field dermatitis as it does 
not include the associated adverse events of biological 
treatments. On the other hand, the grading of the sys-
temic biological treatment effect, which includes the per-
centage of extension over the whole body skin, is not ap-
plicable when the reactions are confined to a limited skin 
surface such as in the irradiated field.
 Thus, even though version 4.3 has either an appro-
priate systemic EGFRi (skin rash) or a radiation derma-
titis toxicity classification  [29] , presently, there is no 
other grading system assessing the in-field severity 
of adverse events due to the association of biotherapy 
and RT.
 These issues can explain the different bioradiotherapy 
in-field toxicity rates reported in different studies  [4] . In-
deed, severity has often been over- or underestimated  [4] , 
and a common treatment strategy could be difficult to 
set up.
 This may compromise the appropriate management of 
skin reactions and, more importantly, may lead to treat-
ment delay or interruption, thereby potentially adversely 
affecting outcome results.
 There is general agreement that a clear and objective 
nomenclature for grading Cet-related radiation dermati-
tis is still lacking  [21, 26, 30, 31] . To our knowledge, the 
only scale that tries to overcome this limitation has been 
the one proposed by Bernier et al.  [13] . These authors 
suggested modifications to the current NCI-CTCAE ver-
sion 4.3 grading system and proposed grade-specific 
management strategies for patients developing radia-
tion dermatitis during treatment with Cet/RT  [13] . To-
gether with radiation dermatitis events, the extension and 
severity of crusting lesions contribute to grade adverse 
events.
 Probably, this first attempt has few limitations related 
to the fact that it does not take into account other spe-
cific biological treatment-related effects such as folliculi-
 Fig. 1. In-field toxicity in a patient submitted to Cet and RT (60 
Gy). While a yellow crusted exudate is visible on the right side, 
bloody scabs on the patient’s left side are probably the consequence 
of traumatisms due to the fact that the patient used to sleep with 
his right cheek on the pillow. 
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tis, oedema, local and systemic inflammation. More re-
cently, a more comprehensive classification has been pro-
posed by a panel of experts  [32] .
 General Prophylactic Measures and Management of 
Skin Toxicity in Patients Receiving Cet/RT 
 Effective management should address the epidermal 
barrier disruption, the inflammatory component and the 
possible superinfection risk as suggested by Bernier et al. 
 [13] .
 Thus, in order to prevent epidermal barrier disrup-
tion, the following suggestion should be followed: (1) 
avoid potentially skin-drying habits/products (e.g. hot 
water, alcohol-based cosmetics). (2) Avoid synthetic 
soaps that might disrupt the liposoluble component of 
the epidermis barrier, eventually worsening xerosis. The 
affected area should not be washed more than twice a day 
using pH 5 soap and/or showering oils for sensitive skin, 
followed by moisturizing with an unscented moisturizer 
recommended for dry skin  [27] . (3) Use moisturizing 
products containing urea (<3%) and/or a high glycerol 
content to prevent excessive skin water loss and conse-
quently improve skin hydration  [25, 27] .
 In order to delay skin exfoliation, according to Bernier 
et al.  [13] and Pinto et al.  [25] , it is advisable to: (1) avoid 
skin irritants such as alcohol-based lotions and perfumes. 
(2) Avoid synthetic clothes; it is advisable to use only lin-
en or cotton clothes on the irradiated areas. (3) Shave with 
a sharp disinfected wet razor to reduce the risk of follicu-
litis. (4) Use pre-shaving emollient creams and moistur-
izing after-shave.
 When xerotic, inflamed skin begins to be covered first-
ly by thin scales and thereafter by yellow thick crusts, pain 
may be a consequence  [14, 22] of skin microlesions due 
to hurting scales themselves. In this case, it is necessary to 
perform the debridement of crusts to reduce the risk of 
superinfection and bleeding and to help reduce pain  [13, 
15, 21] .
 This procedure should be done without traumatizing 
the damaged skin. Hydrogel can help to keep crusts flex-
ible and to reduce the risk of skin trauma and pain. After 
having removed the crusts and cleaned the skin with Ring-
er’s lactate or saline water, the injured skin needs to be 
protected by hydrocolloid films. An ‘ultrathin’ hydrocol-
loid does not interfere with high-energy X-radiation, pre-
serving its build-up effect. In order not to traumatize the 
region with frequent medication, this dressing can be left 
on the site as long as possible (3 days to 1 week). If local 
(green/yellowish exudation)  [15] or systemic [altered sys-
temic inflammatory response syndrome (SIRS) parame-
ters] infection  [13] is suspected, topical and systemic an-
tibiotics should be used after appropriate cultural swabs. 
Obviously, while local and systemic antibiotics effective 
against the causative pathogen are preferred for suspected 
cutaneous infection without altered SIRS parameters, in 
the case of SIRS, empirical systemic antibiotics need to be 
precociously started, as well as a successively modified an-
tibiotic regimen based on microbiologic data  [33] . In-
deed, an infection associated with SIRS-altered parame-
ters must be considered as sepsis  [34] which needs to be 
treated with antibiotics as soon as possible  [33] .
 In conclusion, it is recognized that the management of 
radiation dermatitis associated with Cet/RT is an evolv-
ing area, and it is likely that as our knowledge of the 
pathophysiological mechanism involved in these reac-
tions improves, alternative management approaches may 
be considered.
 The management of skin toxicity is important as it has 
a substantial impact on the quality of life and, potentially, 
on treatment outcome; hence, specific guideline formula-
tion is strongly demanded to provide a systematic per-
spective on this issue and to avoid potential misinterpre-
tations.
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